Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA approved tislelizumab-jsgr (Tevimbra, BeiGene) as monotherapy for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-L1 inhibitor.
The approval is based on the RATIONALE-302 trial, a global, phase 3, randomized, open-label study designed to investigate the efficacy and safety of